Multiple myeloma (MM) is a mostly incurable malignant disease of clonal plasma cells that accumulate in the bone marrow, leading to clinical signs and symptoms related to the displacement of normal hematopoiesis, development of bone disease, and production of monoclonal protein.
Treatment of MM consists of :
- An induction phase with corticosteroid, proteasome inhibitor and immunomodulatory drug
- A short term exposure to high dose of an alkylating agent
- Autologous stem cell transplantation
- Maintenance treatment (corticosteroid and immunomodulatory drug)
Cost of these myeloma treatments are among the highest in cancer : 80 to 100K€ / year / patient.
Patients invariably relapse after multiple lines of treatments. The overall survival of intensively-treated patients is of 6-7 years and the event-free survival of 3-4 years.